Advertisement

Advertisement

PRNAF Stock Latest News

Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

Company AnnouncementsAlterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing

PremiumCompany Announcements

Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing

9d ago

Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026

PremiumCompany Announcements

Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026

10d ago

Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting

PremiumThe Fly

Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting

12d ago

Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy

PremiumCompany Announcements

Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy

12d ago

Alterity Therapeutics presents new data analyses from ATH434 trial

PremiumThe FlyAlterity Therapeutics presents new data analyses from ATH434 trial

17d ago

Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

Company Announcements

Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

17d ago

Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding

Company Announcements

Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding

18d ago

Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme

PremiumCompany Announcements

Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme

19d ago

Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan

PremiumCompany Announcements

Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan

19d ago

Alterity Therapeutics appoints Cunningham to Board of Directors

PremiumThe Fly

Alterity Therapeutics appoints Cunningham to Board of Directors

22d ago

Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board

PremiumCompany Announcements

Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board

22d ago

Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

PremiumCompany AnnouncementsAlterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

23d ago

Alterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event

Company Announcements

Alterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event

24d ago

Alterity Flags Risks Around Forward‑Looking Corporate Outlook

Company Announcements

Alterity Flags Risks Around Forward‑Looking Corporate Outlook

1M ago

Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434

PremiumThe Fly

Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434

1M ago

Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan

PremiumCompany Announcements

Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan

1M ago

Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan

PremiumCompany Announcements

Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan

1M ago

Alterity Therapeutics Plans Issue of 150 Million Options on ASX

PremiumCompany Announcements

Alterity Therapeutics Plans Issue of 150 Million Options on ASX

2M ago

Alterity Therapeutics Launches Facility to Sell Small Share Parcels

PremiumCompany AnnouncementsAlterity Therapeutics Launches Facility to Sell Small Share Parcels

2M ago

Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit

Company Announcements

Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit

2M ago

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

The Fly

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >